Stockscreener 앱 받기
2.83
5.67%
-0.17
시간 외 거래:
2.83
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference - The Manila Times
Aquestive Therapeutics CEO Fireside Chat: Key Updates Coming at Citizens Life Sciences Conference - Stock Titan
Renaissance Technologies LLC Boosts Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential - Seeking Alpha
JPMorgan Chase & Co. Has $269,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics Inc (AQST) deserves deeper analysis - uspostnews.com
Aquestive Therapeutics to Report First Quarter 2025 - GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET - Stock Titan
Aquestive Therapeutics Inc (AQST) receives an Overweight rating from Cantor Fitzgerald - knoxdaily.com
Aquestive Therapeutics Inc’s Market Journey: Closing Weak at 2.83, Down -1.39 - DWinneX
Anaphylaxis Treatment Market Size in 7MM is expected to grow at - openPR.com
The 14% return this week takes Aquestive Therapeutics' (NASDAQ:AQST) shareholders three-year gains to 105% - simplywall.st
Geode Capital Management LLC Trims Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Russell Investments Group Ltd. Has $386,000 Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Check out these key findings about Aquestive Therapeutics Inc (AQST) - Sete News
Is Aquestive Therapeutics Inc (AQST) worth investing in despite its overvalued state? - uspostnews.com
Recent Insider Activity Suggests Potential Gains for Aquestive Therapeutics Inc (AQST) - knoxdaily.com
Investor’s Delight: Aquestive Therapeutics Inc (AQST) Closes Strong at 2.58, Up 2.79 - DWinneX
Does Aquestive Therapeutics Inc (NASDAQ: AQST) Still Need To Convince Analysts? - Stocksregister
Vanguard Group Inc. Grows Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Wellington Management Group LLP Has $639,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - Yahoo Finance
Raymond James Financial Inc. Makes New Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive completes marketing application for Anaphylm in U.S. - MSN
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - The Manila Times
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - GlobeNewswire Inc.
Raymond James Financial Inc. Invests $498,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
What is HC Wainwright’s Estimate for AQST Q1 Earnings? - Defense World
HC Wainwright Reaffirms “Buy” Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World
New Jersey Pharma Co. Shares Positive Pediatric Study - streetwisereports.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by HighTower Advisors LLC - Defense World
Aquestive’s Anaphylm shows promise in pediatric study By Investing.com - Investing.com South Africa
Aquestive’s Anaphylm shows promise in pediatric study - Investing.com India
Aquestive stock gains as Anaphylm NDA completes (AQST:NASDAQ) - Seeking Alpha
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data - Benzinga
Aquestive Therapeutics’ Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating - TipRanks
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film - BioSpace
Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA - TipRanks
Aquestive Therapeutics Announces Positive Topline PK Results From Its Pediatric Study And Completes The NDA Submission For Anaphylm™ (Epinephrine) Sublingual Film - MENAFN.com
Charles Schwab Investment Management Inc. Grows Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive stock falls amid Libervant approval, Anaphylm update - MSN
Bank of New York Mellon Corp Reduces Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy - Seeking Alpha
Aquestive Therapeutics: Not For Me, But Attractive (NASDAQ:AQST) - Seeking Alpha
1.20%
0.06%
자본화:
|
볼륨(24시간):